ludo king hack app PARP inhibitor olaparib achieves primary endpoint in phase 3 clinical trial for prostate cancer Vertex's cystic fibrosis combination therapy receives priority review and is expected ...

A medical dispute between an anti-epidemic hero and an ophthalmology giant Cystic fibrosis giant Vertex: triple combination therapy sales reached nearly $4 billion in one year on the market! A review ...

INR:6644. ipl toss betting app A number of designated medical institutions and medical insurance pharmacies were withdrawn from GSP and their service agreeme ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...

In STAT's "jealousy list" for 2024, STAT staffers explain what makes a selection of stories they read in other publications ...

A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

Changing Futures, a nonprofit dedicated to advancing cystic fibrosis (CF) research, will hold a polar plunge at noon New Year ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...